NCT06905509 - Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

August 1, 2030

Conditions

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsRecurrent High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Nodal Marginal Zone LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Nodal Marginal Zone LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autoHCT

DRUG

Carboplatin

Given carboplatin

DRUG

Cytarabine

Given cytarabine

DRUG

Dexamethasone

Given dexamethasone

BIOLOGICAL

Epcoritamab

Given SC

DRUG

Etoposide Phosphate

Given etoposide phosphate

DRUG

Gemcitabine

Given gemcitabine

DRUG

Ifosfamide

Given ifosfamide

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Oxaliplatin

Given oxaliplatin

BIOLOGICAL

Rituximab

Given rituximab

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Joseph Tuscano

OTHER